drugset / Trial / NCT00165841

Maintenance Intermittent Therapy for Symptomatic GERD Patients

NCT00165841

Phase 2 Completed 200 enrolled Eisai Inc.
RandomizedParallel-groupDouble-blindTreatment

Summary

The purpose of this study to determine the efficacy of 20 mg of rabeprazole given as a maintenance intermittent therapy following acute treatment for Symptomatic Gastroesophageal Reflux Disease (s-GERD).

Timeline

Start
2004-10
Primary completion
2005-12
Completion
2008-06

Drugs

EvaluationDrugModalityDoseRoute
Subject Rabeprazole Small molecule 20 mg Oral